Unlabelled: External cardioversion has been a remarkably effective and safe method for termination of atrial fibrillation. Originally introduced by Lown and coworkers in 1962, it has been an accepted mode of acute therapy. The disadvantages of this approach are the need for general anaesthesia and the demand for high energies up to 360 J. Intraatrial defibrillation of atrial fibrillation using low energy shocks has been intermittently investigated as an alternative to the external method for over two decades. The following aspects have to be considered during the use of intraatrial defibrillation: the efficacy of this method, the safety, i.e. the potential risk of inducing a proarrhythmic, the patient acceptance during recurrent shock discharges, the phenomenon of the atrial stunning, the risk of a thromboembolism, and the necessity of anticoagulation. Our own experience of 25 patients and the data in the literature indicate that internal atrial defibrillation is a safe and effective method for termination of atrial fibrillation, and is particularly useful in patients who have been refractory to external cardioversion. The mean atrial defibrillation threshold for termination of chronic atrial fibrillation was 9.1 +/- 7.4 J in our patient population, corresponding with a leading edge voltage of 376 +/- 175 V and an impedance of 53 +/- 8 omega. At an energy level of 300 V, 40% of the patients could be effectively converted into sinus rhythm. Apart from the induction of three ventricular depolarizations no other proarrhythmic events could be observed during the delivery of approximately 200 shock discharges, in particular no sustained ventricular tachyarrhythmias. The mean pain score at 60 V was 3.0 +/- 1.1 corresponding with a mild discomfort, and at 140 V 4.6 +/- 0.7 corresponding with a moderate to severe discomfort. Serial multiplane transesophageal echocardiographic examinations demonstrated a reduction of the flow in the left atrial appendage following intraatrial defibrillation. These reduced flows in the left atrial appendage recovered within 7 days. On June 3, 1996 an atrial defibrillator was successfully implanted for the first time in Germany in a patient with symptomatic, drug refractory atrial fibrillation.
Conclusions: Intraatrial defibrillation is a safe and effective method for termination of atrial fibrillation. The electrotherapy with an implantable atrial defibrillator should be considered as an alternative approach in patients with symptomatic, long lasting, and drug refractory episodes of atrial fibrillation.
Download full-text PDF |
Source |
---|
Circ Genom Precis Med
January 2025
Centre for Heart Lung Innovation, University of British Columbia, Vancouver. (K.H., M.A., L.R., Y.L., A.S., H.H., L.R.B., Z.W.L.).
Background: Protein-truncating mutations in the titin gene are associated with increased risk of atrial fibrillation. However, little is known about the underlying pathophysiology.
Methods: We identified a heterozygous titin truncating variant (TTNtv) in a patient with unexplained early onset atrial fibrillation and normal ventricular function.
Circ Genom Precis Med
January 2025
Garvan Institute of Medical Research, University of New South Wales, Sydney, Australia. (A.B., J.S., A.C., J.I.).
Background: Females with hypertrophic cardiomyopathy present at a more advanced stage of the disease and have a higher risk of heart failure and death. The factors behind these differences are unclear. We aimed to investigate sex-related differences in clinical and genetic factors affecting adverse outcomes in the Sarcomeric Human Cardiomyopathy Registry.
View Article and Find Full Text PDFInt J Cardiol Heart Vasc
February 2025
Department of Cardiovascular Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
Atrial fibrillation (AF) is the most common tachyarrhythmia and seriously affects human health. Key targets of AF bioinformatics analysis can help to better understand the pathogenesis of AF and develop therapeutic targets. The left atrial appendage tissue of 20 patients with AF and 10 patients with sinus rhythm were collected for sequencing, and the expression data of the atrial tissue were obtained.
View Article and Find Full Text PDFNMC Case Rep J
December 2024
Department of Neurology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
We report a case of persistent consciousness disturbance due to non-convulsive status epilepticus (NCSE) following a successful mechanical thrombectomy (MT). A 98-year-old female with atrial fibrillation presented with impaired consciousness and right hemiparesis 6 hrs after her last known well state. Magnetic resonance angiography revealed occlusion of the left internal carotid artery, necessitating MT to achieve complete recanalisation.
View Article and Find Full Text PDFFront Pharmacol
January 2025
Department of Clinical Pharmacology and Toxicology, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
Background: Dabigatran etexilate (DABE), a prodrug of dabigatran (DAB), is a direct thrombin inhibitor used to prevent ischemic stroke and thromboembolism during atrial fibrillation. The effect of genetic polymorphisms on its metabolism, particularly , has not been extensively explored in humans. This study aimed to investigate the effects of , , and polymorphisms on the pharmacokinetics of DAB and its acylglucuronide metabolites in healthy subjects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!